HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums Distribution Gains Expected To Boost First Quarter Sales 25%

This article was originally published in The Rose Sheet

Executive Summary

Inter Parfums first quarter sales are expected to jump more than 25% to $28 mil.-$29 mil. and net earnings for the period are projected to increase more than 25% to $1.8 mil., Chairman and CEO Jean Madar said during a presentation to analysts March 7.

You may also be interested in...



Burberry Touch Bath Line Expands "Natural" Positioning Of Fragrance Duo

Inter Parfums will expand its Burberry Touch fragrance duo for men and women in May with a bath line that will roll out to approximately 380 doors by the end of the year, Burberry said. Four SKUs for women and three for men will reflect the "natural" positioning of the scents.

Christian Lacroix Spring Scent First Fragrance Line Extension

Parfums Boucheron U.S.A. will introduce Christian Lacroix Eau Floral, a "uniquely feminine floral" edt, exclusively at Saks Fifth Avenue in February. The first extension of the original Christian Lacroix fragrance, the seasonal scent will debut in 63 Saks doors nationwide, the distributor said.

Inter Parfums Prestige Launch Plan Spans Through 2002 - CEO Madar

Inter Parfums is initiating an aggressive product launch strategy over the next few years in an effort to build its $63 mil. prestige beauty care business, Chairman and CEO Jean Madar said.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel